Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


89bio, Inc.

Latest From 89bio, Inc.

Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?

Akero hopes to begin Phase III study of efruxifermin this year, with 89bio working to enter Phase III with pegozafermin in 2024. But just behind them, Boston Pharmaceuticals thinks it has a convenience and immunogenicity edge.

Business Strategies Clinical Trials

Novo Nordisk Has Plans For Semaglutide In NASH Too

With its GLP-1 analog already a stalwart in type 2 diabetes and weight loss, Novo Nordisk is investigating semaglutide as monotherapy and in combination regimens to treat non-alcoholic steatohepatitis.

Business Strategies Clinical Trials

89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients

At AASLD, 89bio presented subgroup analysis from its successful Phase IIb NASH study indicating that the drug may meaningfully reduce fibrosis even in the sickest patients, those with cirrhosis.

Clinical Trials Business Strategies

Akero Looks Ahead To Phase III In Cirrhotic NASH Despite Phase IIb Miss On Fibrosis

Already prepping Phase III trials of efruxifermin in pre-cirrhotic NASH patients, Akero says it will go ahead with Phase III plans in cirrhotic patients despite missing the fibrosis endpoint in a Phase IIb trial.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • 89bio Ltd.